Howard Wessel

Howard Wessel has over 25 years of experience in research and development. From 1993 to 2000, they were a Research Specialist at the University of Pittsburgh, where they conducted molecular cloning, PCR, and radiolabeled hybridization of the Varicella Zoster Virus (VZV) genes, as well as characterization and purification of the human corneal extracellular matrix proteins. Howard also developed monoclonal antibodies to Type XII Collagen and Rho-associated protein kinase. From 2000 to 2007, they worked as a Research Consultant at Generin Diagnostics, developing and validating enzyme assays to diagnose and monitor Gaucher’s patients on Enzyme Replacement Therapy. Howard also managed multiple projects, inventory of materials, shipping, receiving and billing for patient diagnostic kits. From 2007 to 2013, they were the Laboratory Manager at Stemnion. From 2013 to 2017, they were the Research and Development Manager at Noveome Biotherapeutics, Inc., where they were responsible for assay development for product testing and quality control, as well as formulation and product development of biological wound therapies and manufacturing process development and improvement. In 2017, they were promoted to Associate Director of Research and Development at Noveome Biotherapeutics, Inc., where they were involved in development of a novel cell secretome drug product, from source material through manufacturing and testing. Howard also developed secretome drug formulations, tests to monitor protein aggregation and stability of drug products and intermediates, and cell-based assays to assess proliferation, cell attachment and doubling time, cell apoptosis and response to inflammation.

Howard Wessel received their MBA in Health Sciences from Chatham University in 2007, and their B.S. in Life Science/Microbiology from Penn State University in 1993.